21世纪系统性红斑狼疮治疗:新药与老药新视角
该综述批判性评估了SLE现有治疗(抗疟药、糖皮质激素、免疫抑制剂)的疗效与安全性,强调甲泼尼龙冲击后快速减量至泼尼松≤5 mg/日,并讨论贝利尤单抗和利妥昔单抗在难治性或器官威胁性疾病的指征,最后提出基于证据和经验的个体化治疗策略。
要点
- SLE管理目标包括预防器官损伤累积、减少药物伤害、改善健康相关生活质量和延长生存。
- 中重度发作可用甲泼尼龙冲击,随后口服泼尼松低-中剂量并快速减至维持量≤5 mg/日。
- 严重疾病应及早使用免疫抑制剂,既控制病情也作为激素节约剂。
核心结论
- SLE治疗需兼顾控制急性发作与预防器官损伤和药物危害,现有方案并非普遍有效且糖皮质激素暴露可造成相当程度的损伤。
研究设计与样本
- 综述性文章,对SLE现有治疗及潜在新药的疗效与安全性进行批判性评估。
主要发现
- 抗疟药(主要为HCQ)是SLE治疗基石,常与糖皮质激素和免疫抑制剂联合使用。
- 中重度发作推荐甲泼尼龙冲击,后续口服泼尼松低-中剂量并快速减至维持量≤5 mg/日。
- 严重疾病应及早启用免疫抑制剂,并可作为激素节约剂。
- 贝利尤单抗和利妥昔单抗可用于难治性或器官威胁性疾病。
关键数值与推荐
- 维持剂量泼尼松≤5 mg/日。
- 甲泼尼龙冲击适用于中重度发作。
- 生物制剂指征为难治性或器官威胁性疾病。
临床怎么用
- 根据临床场景和主要器官受累情况,制定基于证据和经验的个体化治疗策略。
局限性
- 本文为综述,未报告原始研究样本量、效应量或置信区间等具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Besides treating acute flares, the management of SLE should aim at preventing organ damage accrual and drug-associated harms, improving health-related quality of life and prolonging survival. At present, therapy is based on combinations of antimalarials (mainly HCQ), considered the backbone of SLE treatment, glucocorticoids and immunosuppressive drugs. However, these regimens are not universally effective and a substantial degree of damage can be caused by exposure to glucocorticoids. In this review we provide a critical appraisal of the efficacy and safety of available treatments as well as a brief discussion of potentially novel compounds in patients with SLE. We emphasize the use of methylprednisolone pulses for moderate-severe flares, followed by low-moderate doses of oral prednisone with quick tapering to maintenance doses of ≤5 mg/day, as well as the prompt institution of immunosuppressive drugs in the setting of severe disease but also as steroid-sparing agents. Indications for the use of biologic agents, namely belimumab and rituximab, in refractory or organ-threatening disease are also presented. We conclude by proposing evidence- and experience-based treatment strategies tailored to the clinical scenario and prevailing organ involvement that can aid clinicians in managing this complex disease.
引用
- Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020. PMID: 33280011. doi:10.1093/rheumatology/keaa403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。